Figure 7.

Ibrutinib cooperates with CK1 inactivation in modulating BCR dependent signaling cascades, reducing also CK1α expression. (A, B) Representative WB of NF-kB p65, BTK, AKT, ERK1/2 dependent phosphorylation and total protein expression in Jeko-1 cells electroporated with CSNK1A1 directed siRNA for 48h (A), and in Jeko- 1 exposed to D4476 40 µM for 48h (B), treated with Ibrutinib (IBR) 1 µM or 10 µM for the last 24h. β actin was used as loading control. The figure shows a representative WB, that was performed on at least 3 independent experiments. (C) Representative WB (upper panel) and densitometric analysis (lower panel) of CK1α protein expression in Jeko-1, Rec-1, Granta-519 MCL cells, treated with Ibrutinib 1µM, 5µM and 10 µM for 24h, of three (Jeko-1), two (Rec-1), four (Granta-519) independent experiments. β actin was used as loading control.